Bookmark this pageiconPrint this pageE-mail this page

This is an international site for FEMARA® (letrozole) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

Femara and Breast Cancer Information for International Healthcare Professionals Femara and Breast Cancer Information for US residents Femara and Breast Cancer Information for Patients Outside the US

Take the BIG 1-98 data challenge

BIG 1-98 is a large international clinical trial studying postmenopausal patients with hormone receptor positive (HR+) early breast cancer in the initial adjuvant setting.1,2

To test your knowledge about BIG 1-98, answer the following 5 questions by clicking on your selected response.

1. How many patients have been studied in the BIG 1-98 trial?



2. The 3 most commonly reported adverse events in BIG 1-98 were:





3. At 26-month median follow-up, risk of overall recurrence was reduced by __% versus tamoxifen in patients with HR+ early breast cancer.



4. At 26-month median follow-up, risk of distant metastases was reduced by __% versus tamoxifen in patients with HR+ early breast cancer.




5. At 73-month median follow-up versus tamoxifen, FEMARA® significantly improved






Click here for more information.

BIG 1-98 has demonstrated that FEMARA® can help protect your patients from the early risk of distant metastases.2,5

When choosing an aromatase inhibitor in the initial adjuvant setting, look at the evidence—and choose FEMARA® for your postmenopausal patients with HR+ early breast cancer.

For more information on the pivotal BIG 1-98 trial, click here.

For more information on the unique efficacy profile of FEMARA®, click here.

FEMARA® is indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Click here for Important Safety Information for FEMARA®.

References: 1. Fentiman IS. Optimising adjuvant endocrine treatment of breast cancer with aromatase inhibitors. Int J Clin Pract. 2006;60(6):689-693. 2. The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353(26):2747-2757. 3. Coates AS, Keshaviah A, Thürlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007;25(5):1-12. 4. Mouridsen H, for the BIG 1-98 Collaborative Group. Letrozole monotherapy vs. tamoxifen monotherapy or vs. letrozole in sequence with tamoxifen for postmenopausal women with endocrine-responsive early breast cancer. Presented at: San Antonio Breast Cancer Symposium (SABCS); December 10-14, 2008; San Antonio, Texas. 5. FEMARA® (letrozole) [summary of product characteristics]. Basel, Switzerland: Novartis Pharma AG; 2009. 6. Lamerato L, Havstad S, Gandhi S, Jones D, Chlebowski R. Breast cancer recurrence and related mortality in US pts with early breast cancer. In: Proceedings from the American Society of Clinical Oncology; May 13-17, 2005; Orlando, FL. Abstract 738. 7. The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9:45-53.